Almost half of patients with metastatic bladder cancer only surviving nine months after receiving the first line of treatment with cisplatin-based chemotherapy. Now, workingon different therapies to extend lives, researchers have found that immunotherapies may be provide viable options in both first and second line treatments after two phase II clinical trials.